National Institutes of Health

Description

The purpose of this FOA is to support antimicrobial pharmacokinetic and pharmacodynamic (PK/PD) studies of drug combinations or sequentially administered (sequenced) antimicrobial agents in relevant in vitro and animal models to enhance understanding of the host, drug and microbial factors that contribute to the emergence of antimicrobial drug resistance in clinically relevant pathogens with a goal of minimizing the potential for development of resistance. A secondary objective is to establish partnerships among anti-microbial pharmacologists, microbiologists and animal modelers to bridge the gap between antimicrobial pharmacology and its application to fundamental and translational research for the clinical management of drug resistance.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV